Ligelizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IGHE |
| Clinical data | |
| Other names | QGE031 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6534H10000N1716O2038S44 |
| Molar mass | 146612.49 g·mol−1 |
Ligelizumab (INN; development code QGE031) is a humanized monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria.[1] It binds to IGHE an acts as an immunomodulator.[2]
This drug was developed by Novartis Pharma AG. Research funded by Novartis Pharma (ClinicalTrials.gov number, NCT02477332) concluded that Ligelizumab was more effective in treating chronic spontaneous urticaria than omalizumab or placebo [3].
Adverse drug effects
![[icon]](/wiki/File:Wiki_letter_w_cropped.svg){kind=small} | This section is empty. You can help by adding to it. (October 2014) |
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ligelizumab, American Medical Association.
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- ^ Maurer, Marcus; Giménez-Arnau, Ana M.; Sussman, Gordon; Metz, Martin; Baker, Diane R.; Bauer, Andrea; Bernstein, Jonathan A.; Brehler, Randolf; Chu, Chia-Yu; Chung, Wen-Hung; Danilycheva, Inna (2019-10-02). "Ligelizumab for Chronic Spontaneous Urticaria". New England Journal of Medicine. doi:10.1056/NEJMoa1900408.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |